Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 246

1.

Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.

Sydor S, Manka P, Best J, Jafoui S, Sowa JP, Zoubek ME, Hernandez-Gea V, Cubero FJ, Kälsch J, Vetter D, Fiel MI, Hoshida Y, Bian CB, Nelson LJ, Moshage H, Faber KN, Paul A, Baba HA, Gerken G, Friedman SL, Canbay A, Bechmann LP.

Sci Rep. 2017 Aug 14;7(1):8119. doi: 10.1038/s41598-017-08680-w.

2.

Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling.

Chernyavskaya Y, Mudbhary R, Zhang C, Tokarz D, Jacob V, Gopinath S, Sun X, Wang S, Magnani E, Madakashira BP, Yoder JA, Hoshida Y, Sadler KC.

Development. 2017 Aug 15;144(16):2925-2939. doi: 10.1242/dev.147629. Epub 2017 Jul 11.

PMID:
28698226
3.

MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect.

Shtraizent N, DeRossi C, Nayar S, Sachidanandam R, Katz LS, Prince A, Koh AP, Vincek A, Hadas Y, Hoshida Y, Scott DK, Eliyahu E, Freeze HH, Sadler KC, Chu J.

Elife. 2017 Jun 23;6. pii: e22477. doi: 10.7554/eLife.22477.

4.

Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.

Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y.

Clin Transl Gastroenterol. 2017 Jun 22;8(6):e101. doi: 10.1038/ctg.2017.26.

5.

Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53.

Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D.

Clin Cancer Res. 2017 Jun 19. doi: 10.1158/1078-0432.CCR-17-0342. [Epub ahead of print]

PMID:
28630214
6.

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.

Erstad DJ, Tager AM, Hoshida Y, Fuchs BC.

Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017.

PMID:
28616586
7.

Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Hectors SJ, Wagner M, Bane O, Besa C, Lewis S, Remark R, Chen N, Fiel MI, Zhu H, Gnjatic S, Merad M, Hoshida Y, Taouli B.

Sci Rep. 2017 May 26;7(1):2452. doi: 10.1038/s41598-017-02706-z.

8.

Hepatic stellate cells as key target in liver fibrosis.

Higashi T, Friedman SL, Hoshida Y.

Adv Drug Deliv Rev. 2017 May 12. pii: S0169-409X(17)30063-7. doi: 10.1016/j.addr.2017.05.007. [Epub ahead of print]

PMID:
28506744
9.

Sporotrichal Tenosynovitis Diagnosed Helpfully by Musculoskeletal Ultrasonography.

Shimizu T, Akita S, Harada Y, Oguro E, Okita Y, Shigesaka M, Matsuoka H, Nii T, Teshigawara S, Kudo-Tanaka E, Tsuji S, Matsushita M, Ohshima S, Hoshida Y, Hashimoto J, Saeki Y.

Intern Med. 2017;56(10):1243-1246. doi: 10.2169/internalmedicine.56.7912. Epub 2017 May 15.

10.

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.

Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM.

Eur Radiol. 2017 Apr 24. doi: 10.1007/s00330-017-4844-6. [Epub ahead of print]

PMID:
28439654
11.

Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.

Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY, Hoshida Y.

Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203. [Epub ahead of print] No abstract available.

PMID:
28390144
12.

Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?

Goossens N, Bian CB, Hoshida Y.

Curr Hepatol Rep. 2017 Mar;16(1):64-71. doi: 10.1007/s11901-017-0336-z. Epub 2017 Feb 1.

PMID:
28337405
13.

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Baumert TF, Jühling F, Ono A, Hoshida Y.

BMC Med. 2017 Mar 14;15(1):52. doi: 10.1186/s12916-017-0815-7. Review.

14.

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.

Hicks DF, Goossens N, Blas-García A, Tsuchida T, Wooden B, Wallace MC, Nieto N, Lade A, Redhead B, Cederbaum AI, Dudley JT, Fuchs BC, Lee YA, Hoshida Y, Friedman SL.

Sci Rep. 2017 Mar 3;7:42563. doi: 10.1038/srep42563.

15.

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.

Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J.

Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270. [Epub ahead of print]

16.

The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy.

Kim RS, Hasegawa D, Goossens N, Tsuchida T, Athwal V, Sun X, Robinson CL, Bhattacharya D, Chou HI, Zhang DY, Fuchs BC, Lee Y, Hoshida Y, Friedman SL.

Sci Rep. 2016 Dec 20;6:39342. doi: 10.1038/srep39342.

17.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

PMID:
27960085
18.

The role of GATA2 in lethal prostate cancer aggressiveness.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J.

Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22. Review.

19.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.

Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14.

20.

Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents.

Lu H, Rogowskyj J, Yu W, Venkatesh A, Khan N, Nakagawa S, Goossens N, Koh AP, Higashi T, Gunasekaran G, Schwarz ME, Hiotis SP, Xu X, Kinney W, Hoshida Y, Block T, Cuconati A, Du Y.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5819-5824. doi: 10.1016/j.bmcl.2016.10.015. Epub 2016 Oct 10.

PMID:
27793566

Supplemental Content

Loading ...
Support Center